3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with 3-AP in treating patients who have metastatic non-small cell lung cancer.

Key facts

Study ID

NCT00064064

Run by

Vion Pharmaceuticals

Starts

2003-01-01

Expected to finish

2008-08-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States
• Sarah Cannon Cancer Center at Centennial Medical Center — Nashville, Tennessee, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• University Medical Center Nijmegen — Nijmegen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.